Skip to main content

Table 3 Mean scores (standard deviation) of clinically distinct groups

From: Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors

 

Performance status

Tumor type

Treatment modality

 

KPS≤70

KPS>70

p *

Glioma

Meningioma

Others

p †

OP only

OP+adjuvant therapy

p *

QLQ-C30

          

PF

29.8 (27.4)

76.4(19.0)

<.001

66.2 (29.0)

75.1 (20.0)

73.7 (22.8)

.02a

73.8 (22.2)

67.6 (27.9)

.11

RF

27.3 (31.1)

74.9 (27.3)

<.001

64.5 (35.7)

74.5 (24.7)

71.5 (31.6)

.05

71.8 (27.8)

66.9 (35.7)

.84

EF

56.2 (26.6)

73.5 (22.7)

<.001

68.4 (24.8)

74.1 (20.6)

72.9 (26.0)

.18

71.2 (24.1)

71.9 (23.5)

.89

CF

42.9 (30.3)

73.3 (23.0)

<.001

64.1 (27.7)

73.2 (24.6)

74.2 (22.7)

.008b

72.3 (25.3)

66.4 (26.2)

.03

SF

36.3 (32.7)

76.2 (27.4)

<.001

63.6 (33.6)

81.0 (26.4)

71.9 (29.4)

<.001c

77.2 (28.2)

64.2 (32.5)

<.001

QOL

29.4 (22.3)

57.3 (23.8)

<.001

50.8 (26.3)

58.1 (23.9)

54.1 (24.6)

.09

57.3 (24.7)

50.0 (25.4)

.01

FA

56.5 (24.2)

35.0 (21.7)

<.001

40.4 (25.6)

34.2 (20.4)

37.3 (21.9)

.13

36.2 (21.6)

39.2 (24.8)

.24

NV

21.4 (25.1)

10.4 (15.9)

.005

13.9 (18.7)

9.0 (14.4)

11.8 (19.2)

.12

10.9 (17.9)

12.7 (17.0)

.05

PA

51.4 (29.8)

21.7 (24.6)

<.001

26.2 (29.6)

23.7 (24.0)

25.2 (26.6)

.79

25.8 (26.3)

24.2 (27.9)

.36

QLQ-BN20

         

FU

47.1 (26.6)

32.7 (22.8)

.002

38.5 (24.2)

28.2 (21.1)

36.5 (24.7)

.003d

32.0 (23.8)

37.5 (23.3)

.02

VD

40.3 (31.4)

25.6 (27.4)

.002

22.3 (26.2)

30.6 (27.3)

30.5 (31.5)

.05

29.1 (29.4)

24.8 (26.4)

.23

MD

73.7 (29.4)

23.4 (23.3)

<.001

34.2 (32.6)

23.4 (23.0)

29.2 (28.9)

.02e

26.9 (26.3)

32.2 (32.0)

.33

CD

47.7 (34.5)

19.2 (25.2)

<.001

30.1 (31.4)

16.0 (23.4)

19.1 (24.7)

<.001f

19.3 (25.9)

26.6 (29.8)

.03

  1. * p-value was calculated by Mann–Whitney U test.
  2. † p-value was calculated by ANOVA.
  3. a, c Post-hoc test by Sheffe; glioma<meningioma.
  4. b Post-hoc test by Sheffe; glioma<meningioma, glioma<others.
  5. d, e, f Post-hoc test by Sheffe; glioma>meningioma.
  6. KPS Karnofsky performance scale, OP operation, QLQ-C30 Quality of Life Core Questionnaire, PF physical functioning, RF role functioning, EF emotional functioning, CF cognitive functioning, SF social functioning, FA fatigue, NV nausea and vomiting, PA pain, QLQ-BN20 Quality of Life Questionnaire Brain Cancer Module, FU future uncertainty, VD visual disorder, MD motor dysfunction, CD communication deficit.
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us